PresseBox
Pressemitteilung BoxID: 370899 (Myconostica Ltd)
  • Myconostica Ltd
  • South Court, Sharston Road
  • M22 4SN Manchester
  • http://www.myconostica.co.uk/
  • Ansprechpartner
  • Heidi Wahlefeld-Moghimi
  • +44 (161) 998-7239

Myconostica Announces CE Marking of MycAssay Aspergillus For Serum

(PresseBox) (Manchester, United Kingdom, ) Myconostica Ltd, the UKbased medical diagnostic company developing and commercialising rapid and highly specific tests for lifethreatening fungal infections, today announces the CE marking of its lead product MycAssay(TM) Aspergillus for detection of Aspergillus DNA in serum.

The CE marking is in addition to the existing CE marking for respiratory samples means, that MycAssay(TM) Aspergillus is now CE marked for all major sample types.

MycAssay(TM) Aspergillus is a molecular diagnostic test for the detection of Aspergillus spp DNA. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssay(TM) Aspergillus aid physicians to make a diagnosis in patients suspected of having an infection caused by Aspergillus. It provides rapid and accurate results to physicians, enabling appropriate drug treatments to be administered thereby improving patient outcomes.

Dr. John Thornback, Myconostica's Chief Business Officer, said: "It is becoming increasingly recognised that Aspergillus DNA is present in serum and its measurement can be important in aiding the diagnosis of Aspergillus infections. There are a number of different high risk patient groups for whom it is difficult to obtain respiratory samples. The CE marking of MycAssay(TM) Aspergillus for serum now enables serum samples from these at risk patients to be tested using a fully validated assay.

Myconostica Ltd

Myconostica Ltd, a UKbased medical diagnostic company, specialises in rapid and highly specific tests for lifethreatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow. Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy.

Myconostica is developing and commercialising a portfolio of realtime molecular diagnostic tests for lifethreatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.

www.myconostica.co.uk